The treatment of uraemic hyperphosphataemia with calcium acetate and calcium carbonate: a comparative study.
A comparative study of long-term haemodialysis patients investigated the effects of calcium acetate and calcium carbonate on concentrations of serum phosphate, calcium, and parathyroid hormone. It was demonstrated that both substances led to a significant decrease in phosphate and serum parathyroid hormone. Administration of calcium acetate reduced the serum phosphate concentration in 7 weeks from an initial value of 2.08 +/- 0.53 mmol/l to 1.51 +/- 0.39 mmol/l (P less than 0.01). Following a 1-week wash-out period, calcium carbonate reduced the serum phosphate concentration in the same patients from 1.99 +/- 0.62 mmol/l to 1.34 +/- 0.40 mmol/l (P less than 0.01). Of particular significance, however, is the fact that in relation to daily elementary calcium intake, calcium acetate was a considerably more effective binder of intestinal phosphate than calcium carbonate. During administration of calcium acetate only 1.02 g of elementary calcium were required daily in order to reduce the serum phosphate concentration. The same patients, however, required 1.88 g of elementary calcium during calcium carbonate therapy. Complementary studies investigated the influence of an accompanying calcitriol medication. In this instance, too, calcium acetate was shown to be more effective; although the patients developed hypercalcaemia with calcium acetate, this happened more often with calcium carbonate. In summary it can be said that daily calcium loading of the uraemic organism under calcium acetate therapy is reduced by nearly half as compared to calcium carbonate therapy, and that this can be achieved with the same effective decrease of the serum phosphate concentration.
Schaefer
K
K
Medical Department II, St Joseph-Krankenhaus I, Berlin, Germany.
Scheer
J
J
Asmus
G
G
Umlauf
E
E
Hagemann
J
J
von Herrath
D
D
D000085:Acetates / Q000008:administration & dosage / Q000627:therapeutic use*; D019342:Acetic Acid; D002117:Calcitriol / Q000008:administration & dosage / Q000009:adverse effects; D002118:Calcium / Q000097:blood; D002119:Calcium Carbonate / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000209:etiology; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood; D010710:Phosphates / Q000097:blood*; D014511:Uremia / Q000097:blood / Q000188:drug therapy*
D000085:Acetates; D010281:Parathyroid Hormone; D010710:Phosphates; D002117:Calcitriol; D002119:Calcium Carbonate; D019342:Acetic Acid; D002118:Calcium